Early Detection Saves Lives

ColonAiQ Revolutionary
Blood Test
for
Colorectal Cancer Screening

Key Benefits Of ColonAiQ

Higher Sensitivity

Higher Sensitivity: ColonAiQ demonstrates superior sensitivity compared to FIT (Fecal Immunochemical Test): (5) (6)


  • Overall sensitivity: 88.3% vs. 59.7%
  • Stage I detection: 85.7% vs. 28.6%

Patient Preference

Patient Preference: Most patients prefer blood tests over stool-based tests, potentially increasing screening compliance. (4)


Earlier Detection

Improved Early Detection: ColonAiQ significantly increases detection rates for precancerous adenomas and early-stage CRC compared to existing molecular screening tests. (8)


A Breakthrough in Early Detection

ColonAiQ is a cutting-edge, multi-locus blood-based assay that targets circulating tumor DNA methylation. This innovative technology offers unparalleled success in non-invasive early detection of both colorectal cancer (CRC) and advanced adenoma (AA). (8)

Why Timely CRC Screening Matters?

Colorectal cancer is a critical health concern in Singapore and the Philippines:

Why Early Detection Matters?

Stage distribution of CRC in Singapore (2018-2021): (2)
Earlier detection leads to better treatment outcomes and improved survival rates.

Benefits of ColonAiQ

Get In Touch

ColonAiQ is currently undergoing review by the Health Sciences Authority (HSA) for registration as a medical device in Singapore and the Philippines.

Sign up for our waitlist to be among the first to be notified when ColonAiQ becomes available!